A recent study published in The Lancet Regional Health - Europe reveals that a gradual low-dose peanut oral immunotherapy (OIT) can effectively desensitize 82.5% of preschool children with peanut allergies. Conducted at the Karolinska Institutet in Sweden, the trial involved 75 children aged between one and three years. Participants received small daily doses of peanut protein, gradually increasing under strict medical supervision. At the end of the treatment, many children could tolerate the equivalent of at least 3.5 peanuts without allergic reactions. This approach, characterized by a slow up-dosing strategy, appears to enhance safety, as most side effects were mild and occurred during dose escalation phases. Peanut allergies are increasingly prevalent, posing significant health risks and psychological burdens for families. The study emphasizes the importance of early intervention, suggesting that starting treatment at a young age may lead to better outcomes. While the findings are promising, experts stress that peanut immunotherapy should only be conducted under specialist supervision and that larger international studies are necessary to confirm these results.